AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7921207 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms GHRH(1-29)NH2
Number of subjects: 10
Study 7921207 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms GHRH(1-29)NH2
Number of subjects: 10
Study 7921207 — intervention group
Group type: COMPARATOR
Intervention: 1 microgram GHRH(1-29)NH2
Number of subjects: 10
Study 3166359 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin 400 mg administered orally or intravenously
Number of subjects: 31
Study 30335527 — intervention group
Group type: EXPERIMENTAL
Intervention: High anger appeal message
Number of subjects: 551
Study 30335527 — intervention group
Group type: EXPERIMENTAL
Intervention: Low anger appeal message
Number of subjects: 551
Study 30335527 — intervention group
Group type: EXPERIMENTAL
Intervention: High efficacy appeal message
Number of subjects: 551
Study 30335527 — intervention group
Group type: EXPERIMENTAL
Intervention: Low efficacy appeal message
Number of subjects: 551
Study 30335527 — intervention group
Group type: COMPARATOR
Intervention: No exposure control group
Number of subjects: 551
Study 28301825 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined knee brace and foot orthotic
Number of subjects: 35
Study 28301825 — intervention group
Group type: COMPARATOR
Intervention: Control (no knee brace or foot orthotic)
Number of subjects: 35
Study 28301825 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee brace
Number of subjects: 35
Study 28301825 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthotic
Number of subjects: 35
Study 26096139 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (single dose, 1000 mg) + low-fat meal
Number of subjects: 60
Study 26096139 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (single dose, 1000 mg) + high-fat meal
Number of subjects: 60
Study 26096139 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg + 5 mg prednisone twice daily) + high-fat meal
Number of subjects: 60
Study 26096139 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg + 5 mg prednisone twice daily) + low-fat meal
Number of subjects: 60
Study 26096139 — intervention group
Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 60
Study 26096139 — intervention group
Group type: COMPARATOR
Intervention: Modified fasting state
Number of subjects: 60
Study 23462149 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet and physical activity), average duration 4.2 ± 2.0 years
Number of subjects: 146
Study 23462149 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 146
Study 23462149 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet and physical activity)
Number of subjects: 146
Study 21304921 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery of IPTc by Village Health Workers (VHWs)
Number of subjects: 10400
Study 21304921 — intervention group
Group type: COMPARATOR
Intervention: Delivery of IPTc through RCH trekking teams
Number of subjects: 10400
Study 21304921 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery of IPTc by VHWs
Number of subjects: 10400
Study 21304921 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTc efficacy
Number of subjects: 10400
Study 19656736 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective ganglionated plexi ablation
Number of subjects: 80
Study 19656736 — intervention group
Group type: COMPARATOR
Intervention: Anatomic ablation targeting the anatomic areas of ganglionated plexi
Number of subjects: 80
Study 17299808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (depression care manager offering algorithm‐based care for depression)
Number of subjects: 599
Study 17299808 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 599
Study 14968327 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacalcitol emulsion (4 micro g/g) once daily
Number of subjects: 273
Study 14968327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study 11481622 — intervention group
Group type: COMPARATOR
Intervention: Engerix‐B (0, 1, 6 regimen)
Number of subjects: 304
Study 11481622 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antigen vaccine (2-dose regimen: 0, 1)
Number of subjects: 304
Study 11481622 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antigen vaccine (3-dose regimen: 0, 1, 6)
Number of subjects: 304
Study 11481622 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antigen vaccine
Number of subjects: 304
Study 9570610 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 40 mg (Group A)
Number of subjects: 123
Study 9570610 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 40 mg followed by naloxone 0.04 mg (Group B)
Number of subjects: 123
Study 9570610 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 40 mg followed by naloxone 0.2 mg (Group C)
Number of subjects: 123
Study 9570610 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo (Group D)
Number of subjects: 123
Study 7822064 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (ST) for 20 weeks
Number of subjects: 26
Study 7822064 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AT) for 20 weeks
Number of subjects: 26
Study 7822064 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group) for 20 weeks
Number of subjects: 26
Study 3171787 — intervention group
Group type: COMPARATOR
Intervention: Forced expiratory technique alone
Number of subjects: 0
Study 3171787 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy with percussion and postural drainage
Number of subjects: 0
Study 31635976 — intervention group
Group type: EXPERIMENTAL
Intervention: aQIV
Number of subjects: 1778
Study 31635976 — intervention group
Group type: COMPARATOR
Intervention: aTIV-1
Number of subjects: 1778
Study 31635976 — intervention group
Group type: COMPARATOR
Intervention: aTIV-2
Number of subjects: 1778
Study 30243130 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin treatment (300 mg/day)
Number of subjects: 112
Study 30243130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 28673350 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 96
Study 28673350 — intervention group
Group type: COMPARATOR
Intervention: Mock Laser
Number of subjects: 96
Study 26133204 — intervention group
Group type: EXPERIMENTAL
Intervention: Kundalini yoga (KY) program for 8 weeks
Number of subjects: 40
Study 22941671 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined measure of the Functional Independence Measure (FIM) and the Nottingham Extended Activities of Daily Living (NEADL)
Number of subjects: 188
Study 22941671 — intervention group
Group type: EXPERIMENTAL
Intervention: 36-item scale
Number of subjects: 188
Study 21118502 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime (1.5 g intravenously)
Number of subjects: 176
Study 21118502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (3 g intravenously)
Number of subjects: 176
Study 18608041 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40-80 mg/d
Number of subjects: 54
Study 18608041 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg followed by 75 mg/d
Number of subjects: 54
Study 18608041 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 160-325 mg daily (Control)
Number of subjects: 54
Study 16965522 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + CHX
Number of subjects: 29
Study 16965522 — intervention group
Group type: COMPARATOR
Intervention: SRP + placebo
Number of subjects: 29
Study 12771471 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular alefacept 15 mg
Number of subjects: 507
Study 12771471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study 11044791 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG‐CoA reductase inhibitor (pravastatin 10 mg/day)
Number of subjects: 56
Study 11044791 — intervention group
Group type: COMPARATOR
Intervention: No medical treatment (nontreated group)
Number of subjects: 56
Study 9088649 — intervention group
Group type: EXPERIMENTAL
Intervention: Family size (increase of one sibling)
Number of subjects: 1159
Study 9088649 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth order
Number of subjects: 1159
Study 9088649 — intervention group
Group type: EXPERIMENTAL
Intervention: Family size and birth order
Number of subjects: 1159
Study 8259610 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-D vaccine coadministered with Di-Te-Pol
Number of subjects: 21
Study 8259610 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 21
Study 3862463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate only
Number of subjects: 93
Study 3862463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate plus cranial irradiation
Number of subjects: 93
Study 3862463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate plus intermediate dose methotrexate
Number of subjects: 93
Study 3862463 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of abnormal scans
Number of subjects: 93
Study 3862463 — intervention group
Group type: EXPERIMENTAL
Intervention: None of the three methods of CNS prophylaxis
Number of subjects: 93
Study 30478001 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin oral solution 10 mg/kg per day for 3 days
Number of subjects: 59
Study 30478001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 26503204 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 302
Study 24493716 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) plus involved-field RT (36 Gy)
Number of subjects: 166
Study 24493716 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) without RT
Number of subjects: 166
Study 24493716 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP without RT (per-protocol analysis excluding 11 patients who received unplanned RT)
Number of subjects: 166
Study 23250593 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 60
Study 23250593 — intervention group
Group type: COMPARATOR
Intervention: Nootropil
Number of subjects: 60
Study 20164561 — intervention group
Group type: EXPERIMENTAL
Intervention: PBT2 250 mg
Number of subjects: 0
Study 20164561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18364392 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple algorithm
Number of subjects: 273
Study 18364392 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate counting (carb count)
Number of subjects: 273
Study 15467775 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat, 120 mg three times daily with hypocaloric diet
Number of subjects: 36
Study 15467775 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy age-matched subjects)
Number of subjects: 36
Study 14650571 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental acupuncture treatment (specific acupuncture body points related to menopausal symptoms)
Number of subjects: 0
Study 14650571 — intervention group
Group type: COMPARATOR
Intervention: Comparison acupuncture treatment (general tonic designed to benefit the flow of Ch'i)
Number of subjects: 0
Study 14650571 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental acupuncture treatment
Number of subjects: 0
Study 14650571 — intervention group
Group type: COMPARATOR
Intervention: Experimental acupuncture treatment and Comparison acupuncture treatment
Number of subjects: 0
Study 10798650 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine
Number of subjects: 243
Study 10798650 — intervention group
Group type: COMPARATOR
Intervention: Normal control
Number of subjects: 243
Study 8824686 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (1% in 50% ethanol) applied for 7 days on one forearm
Number of subjects: 13
Study 8824686 — intervention group
Group type: COMPARATOR
Intervention: Capsaicin vehicle applied on the contralateral forearm
Number of subjects: 13
Study 1597024 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 30
Study 1597024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 4061000 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with aspiration of 3 ml of CSF
Number of subjects: 60
Study 4061000 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia without aspiration of CSF
Number of subjects: 60
Study 4061000 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with a mixture of 3 ml of aspirated CSF and 3 ml of 0.5% isobaric bupivacaine
Number of subjects: 60
Study 30789848 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 testing by immunohistochemistry (IHC) using unstained slides with TMA tissue cores from NSCLC and tonsil tissues.
Number of subjects: 104
Study 30789848 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit-for-purpose PD-L1 assay
Number of subjects: 104
Study 28933314 — intervention group
Group type: EXPERIMENTAL
Intervention: Low support, remotely accessible, computerized working memory training programme
Number of subjects: 90
Study 28933314 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI scanning
Number of subjects: 90
Study 27020830 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energetic focused ESWT (0.3 mJ/mm2, 4 Hz, 1000 impulses, 10 J)
Number of subjects: 26
Study 27020830 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive high-energetic focused ESWT (3 sessions of 0.3 mJ/mm2, 4 Hz, 3 × 1000 impulses, totaling 30 J)
Number of subjects: 26
Study 24507404 — intervention group
Group type: EXPERIMENTAL
Intervention: Early coronary artery bypass grafting (CABG)
Number of subjects: 347
Study 24507404 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 347
Study 24507404 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard myocardial protection and routine use of internal mammary artery or other arterial grafts
Number of subjects: 347
Study 21873358 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg capsules
Number of subjects: 1898
Study 21873358 — intervention group
Group type: COMPARATOR
Intervention: Warfarin 5 mg tablets
Number of subjects: 1898
Study 20807884 — intervention group
Group type: COMPARATOR
Intervention: Fruits and Vegetables (F/V)
Number of subjects: 459
Study 20807884 — intervention group
Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 459
Study 18050196 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice weekly)
Number of subjects: 20
Study 18050196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16286519 — intervention group
Group type: COMPARATOR
Intervention: Calorie-restricted low-dairy diet (CR) - approximately 1 serving dairy/day, 500 mg calcium/day
Number of subjects: 54
Study 16286519 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-restricted high-dairy diet (CR+D) - 3 to 4 servings dairy/day, 1200 to 1400 mg calcium/day
Number of subjects: 54
Study 11201422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy
Number of subjects: 56
Study 11201422 — intervention group
Group type: COMPARATOR
Intervention: Routine physiotherapy
Number of subjects: 56
Study 11201422 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy
Number of subjects: 56
Study 11201422 — intervention group
Group type: COMPARATOR
Intervention: Aim-directed therapy
Number of subjects: 56
Study 9517760 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg folic acid supplementation per week
Number of subjects: 79
Study 9517760 — intervention group
Group type: EXPERIMENTAL
Intervention: 27.5 mg folic acid supplementation per week
Number of subjects: 79
Study 9517760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 8123851 — intervention group
Group type: EXPERIMENTAL
Intervention: ras-positive patients
Number of subjects: 99
Study 8123851 — intervention group
Group type: EXPERIMENTAL
Intervention: ras mutations
Number of subjects: 99
Study 8123851 — intervention group
Group type: EXPERIMENTAL
Intervention: lower bone marrow blast counts
Number of subjects: 99
Study 8123851 — intervention group
Group type: EXPERIMENTAL
Intervention: better cytogenetic category
Number of subjects: 99
Study 8123851 — intervention group
Group type: EXPERIMENTAL
Intervention: aberrant ras allele
Number of subjects: 99
Study 2955205 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol valerate (2 mg/day)
Number of subjects: 18
Study 2955205 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol/medroxyprogesterone acetate
Number of subjects: 18
Study 2955205 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol/levonorgestrel (LNG)
Number of subjects: 18
Study 30572473 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve electrical stimulation (NES)
Number of subjects: 124
Study 30572473 — intervention group
Group type: COMPARATOR
Intervention: Sham NES
Number of subjects: 124
Study 27633168 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised treadmill exercise program for 12 weeks
Number of subjects: 36
Study 25033150 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape Program (weight gain prevention intervention)
Number of subjects: 0
Study 23510724 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius Ls-33
Number of subjects: 50
Study 23510724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22117984 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA (propofol‐remifentanil [target blood concentrations 2.5 ‐ 3.5 μg/ml and 3.5 ‐ 4.5 ng/ml])
Number of subjects: 177
Study 22117984 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined inhalation and intravenous anaesthesia (sevoflurane 1.0 vol% in 50% air plus propofol‐remifentanil [target blood concentrations 1.5 ‐ 2.5 μg/ml and 2.5 ‐ 3.5 ng/ml])
Number of subjects: 177
Study 22117984 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (thiopental sodium 4 ‐ 5 mg/kg and sevoflurane 2.0 ‐ 2.5 vol% in 50% air)
Number of subjects: 177
Study 19271172 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine combined with SPNS formula
Number of subjects: 60
Study 19271172 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine only
Number of subjects: 60
Study 16490647 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (1.25 mg)
Number of subjects: 100
Study 16490647 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 100
Study 16490647 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine (10 mg)
Number of subjects: 100
Study 16490647 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 100
Study 14714106 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiver of consent from the patient's next of kin
Number of subjects: 300
Study 14714106 — intervention group
Group type: COMPARATOR
Intervention: Standard consent process (before waiver)
Number of subjects: 300
Study 14714106 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent obtained from patients or next of kin
Number of subjects: 300
Study 10940797 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide, 400 mug twice daily
Number of subjects: 25
Study 10940797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9028547 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 50
Study 9028547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8365089 — intervention group
Group type: EXPERIMENTAL
Intervention: B28Asp (0.15 U kg‐1 body weight)
Number of subjects: 14
Study 8365089 — intervention group
Group type: COMPARATOR
Intervention: Soluble human insulin (0.15 U kg‐1 body weight)
Number of subjects: 14
Study 6149992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1,000 mg per day)
Number of subjects: 8
Study 6149992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg per day)
Number of subjects: 8
Study 6149992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (120 mg per kg body weight)
Number of subjects: 8
Study 6149992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (120 mg per kg body weight)
Number of subjects: 8
Study 6149992 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 8
Study 30677084 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-persuasion anti-alcohol poster (framed as a question)
Number of subjects: 149
Study 30677084 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct persuasion anti-alcohol poster (framed as a statement)
Number of subjects: 149
Study 30677084 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no poster)
Number of subjects: 149
Study 29372578 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided approach
Number of subjects: 129
Study 29372578 — intervention group
Group type: COMPARATOR
Intervention: Anatomical landmark approach
Number of subjects: 129
Study 27444428 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Treatment (IT)
Number of subjects: 0
Study 27444428 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 0
Study 24470257 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressing to start and stop the interval
Number of subjects: 0
Study 24470257 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous pressing during the interval
Number of subjects: 0
Study 24470257 — intervention group
Group type: EXPERIMENTAL
Intervention: Just pressing at the end of the interval
Number of subjects: 0
Study 22108529 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced continuous steady rate swim of 20 minutes
Number of subjects: 33
Study 22108529 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach-administered modified warm-up consisting of various swimming modes, intensities, and rest intervals for 20 minutes
Number of subjects: 33
Study 22108529 — intervention group
Group type: COMPARATOR
Intervention: Land-based recovery consisting of light-intensity walking, skipping, and stretching for 20 minutes
Number of subjects: 33
Study 20698844 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% DHEA cream
Number of subjects: 75